Philogen SpA (MIL:PHIL) ROE % Adjusted to Book Value: 78.00% (As of Dec. 2025)


MIL:PHIL Philogen SpA MIL:PHIL
61 GF Score
Price €23.25
GF Value €227.22
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Philogen SpA ROE % Adjusted to Book Value?

Philogen SpA MIL:PHIL -0.21% 61 ROE % Adjusted to Book Value is 78.00% as of Dec. 2025. GuruFocus rates MIL:PHIL with a GF Score™ of 61/100 and a GF Value™ of €227.22 (Possible Value Trap). The stock has 3 warning signs investors should review.

Philogen SpA's ROE % for the quarter that ended in Dec. 2025 was 195.78%. Philogen SpA's PB Ratio for the quarter that ended in Dec. 2025 was 2.51. Philogen SpA's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 78.00%.

Philogen SpA ROE % Adjusted to Book Value Related Terms

Philogen SpA ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Philogen SpA's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Philogen SpA ROE % Adjusted to Book Value Chart

Philogen SpA Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -3.53 -0.91 -0.79 6.97 35.71

Philogen SpA Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.44 -3.44 20.00 -3.27 78.00

MIL:PHIL vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Philogen SpA's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Philogen SpA ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Philogen SpA's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Philogen SpA's ROE % Adjusted to Book Value falls into.


MIL:PHIL
61GF Score
Philogen SpA MIL:PHIL
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Philogen SpA ROE % Adjusted to Book Value Calculation

Philogen SpA's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=89.63% / 2.51
=35.71%

Philogen SpA's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=195.78% / 2.51
=78.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 78.00% mean?
Philogen SpA (MIL:PHIL) has a ROE % Adjusted to Book Value of 78.00% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Philogen SpA and its competitors.
Is Philogen SpA's ROE % Adjusted to Book Value too high?
Philogen SpA's current ROE % Adjusted to Book Value is 78.00%. Overall, Philogen SpA has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's ROE % Adjusted to Book Value compare to VRTX and REGN?
Philogen SpA's ROE % Adjusted to Book Value of 78.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Philogen SpA and its competitors. Philogen SpA's current ROE % Adjusted to Book Value is 78.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €227.22, compared to a current price of €23.25 — trading 89.8% below its estimated fair value. The current ROE % Adjusted to Book Value is 78.00%. Philogen SpA's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current ROE % Adjusted to Book Value is 78.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Philogen SpA (MIL:PHIL) Overvalued in 2026?

Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued. The current stock price of €23.25 is trading 89.8% below its estimated GF Value™ of €227.22. GuruFocus considers Philogen SpA to be Possible Value Trap.

Key valuation signals for MIL:PHIL:

  • ROE % Adjusted to Book Value: 78.00%
  • GF Value™: €227.22 vs. price of €23.25 (89.8% below fair value)
  • GF Score™: 61/100 with 3 warning signs

No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Philogen SpA Business Description

Other Exchanges 78Q:Germany
Address Piazza La Lizza No. 7, Siena, ITA, 53100
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
61GF Score

Get the complete analysis for MIL:PHIL

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€23.25
Price
€227.22
GF Value